Non-U.S. regulatory interactions: EMA, national competent authorities, and the RC's coordination role in global trials
Analyzes major non-U.S. regulatory frameworks and their site-level implications, designs communication protocols for sponsor notifications about international regulatory actions, and evaluates the portfolio impact of multi-regional requirements in global trials.
Your study does not stop at the U.S. border
If you manage a portfolio at a U.S. investigator site, you might reasonably assume that the FDA is the only regulatory authority you need to think about. And for studies conducted entirely within the United States under a single IND, that assumption is mostly correct. The sponsor manages the IND. The FDA communicates with the sponsor. The site responds to what reaches it through the sponsor channel, as we discussed in Lesson 3.
But here is the reality of modern clinical research: a significant and growing proportion of clinical trials are global. The same protocol, the same molecule, the same endpoints -- studied across sites in the United States, Europe, Japan, Canada, Australia, and elsewhere. When you participate in a global trial, regulatory actions by non-U.S. authorities can generate site-level obligations that affect your site's conduct of the study, even though those actions originated thousands of miles away in a regulatory system your site does not directly interact with.
The EMA's Pharmacovigilance Risk Assessment Committee requests additional safety data. A national competent authority in Germany suspends enrollment pending review of an unexpected adverse reaction. Japan's PMDA requires a protocol amendment to address dosing concerns specific to the Japanese population. Each of these actions, initiated by regulators your site has never communicated with, may produce ripple effects that reach your desk -- through the sponsor, through protocol amendments, through revised investigator brochures, through new safety communications you must distribute and document.
This lesson addresses a question that most RC training ignores entirely: what does a U.S. site's RC need to know about non-U.S. regulatory interactions, and what systems should the RC build to manage the site-level implications of global regulatory activity?
What you will learn
By the end of this lesson, you will be able to: